by diviadmin | Mar 24, 2025 | News
Stanford University’s Innovative Medicines Accelerator (IMA) and Intonation Research Laboratories have partnered to develop targeted treatments for neuroendocrine tumors, aiming to accelerate drug development and reduce costs. “This collaboration has the potential to...
by diviadmin | Jan 14, 2025 | News
The effects of indole-3-carbinol (I3C) compound have been described deeply as antitumor drug in multiple cancers. Herein, I3C compound was tested for toxicity and antiviral activity against SARS-CoV-2 infection. Antiviral activity was assessed in vitro in both in...
by diviadmin | Jan 14, 2025 | News
Neutralizing antibodies (nAbs) hold promise as therapeutics against COVID-19. Here, we describe protein engineering and modular design principles that have led to the development of synthetic bivalent and tetravalent nAbs against SARS-CoV-2. The best nAb targets the...
by diviadmin | Jan 14, 2025 | News
Activation of tumor suppressors for the treatment of human cancer has been a long sought, yet elusive, strategy. PTEN is a critical tumor suppressive phosphatase that is active in its dimer configuration at the plasma membrane. Polyubiquitination by the ubiquitin E3...
by diviadmin | Jan 14, 2025 | News
Disruption of mitochondrial function and protein homeostasis plays a central role in aging. However, how these processes interact and what governs their failure in aging remain poorly understood. Here, we showed that ceramide biosynthesis controls the decline in...
by diviadmin | Jan 14, 2025 | News
The accumulation of ceramides and related metabolites has emerged as a pivotal mechanism contributing to the onset of age-related diseases. However, small molecule inhibitors targeting the ceramide de novo synthesis pathway for clinical use are currently unavailable....
